Inclusion of Minority Patients in Breast Cancer Clinical Trials: The Role of the Clinical Trial Environment

Abstract

PURPOSE: To determine the effects of clinical trial (CT) characteristics on physicians' referral of minority women to breast cancer CTs. SCOPE: Activities included: a) Identifying 225 breast cancer CTs conducted in 2006 at 352 sites in California, Florida, Illinois, and New York through NCI Website; b) Interviewing 233 research team members; and c) Surveying 706 oncologists, surgeons, and radiation oncologists from the four states. FINDINGS: Almost 40% of the physicians reported discussing enrollment in a CT with their patients, while 33% said they frequently discussed the benefits/burdens of a specific CT. Oncologists were significantly more likely than other specialists to discuss enrollment and the benefits/burdens of a CT. Time spent in patient care and distance to a CT were negatively associated with referral. The most cited barriers to recruitment were study entry criteria and an indicator of patient barriers. Examination of the CT environment indicated that only one-third of the CT sites reported providing study summaries in a language other than English and less than one-half provided onsite interpreters. These results suggest that availability and accessibility play key roles in physician referral to CTs.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2010
Accession Number
ADA544195

Entities

People

  • Celia P. Kaplan

Organizations

  • University of California, San Francisco

Tags

DTIC Thesaurus Topics

  • African Americans
  • Asian Americans
  • California
  • Clinical Trials
  • Data Analysis
  • Ethnic Groups
  • Health Care
  • Health Services
  • Hispanics
  • Medical Personnel
  • Minority Groups
  • Native Americans
  • New York
  • Oncology
  • Personnel Management
  • Physicians
  • Radiation Oncology

Fields of Study

  • Medicine
  • Physics

Readers

  • Library and Information Science
  • Naval Personnel Management
  • Oncology and Biomarker-Based Cancer Detection.